Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer
A phase 1/2 trial of TUB-040 + Carbo + BEV in ovarian cancer, run by Tubulis GmbH, now recruiting.
Overview
Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer is a phase 1/2 interventional study registered as NCT07736937 by Tubulis GmbH, with 72 participants planned, started 2026-03-30 and due to reach its primary completion in 2028-03. Interventions recorded: TUB-040 + Carbo + BEV.
Similar pages
not linked directly; found by shared links- TrialFiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Shares Tubulis (Gilead), Ovarian cancer and the tag pipeline.
- TrialFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Shares Tubulis (Gilead) and the tag pipeline.
- TrialA Trial of Vigil for Participants With Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialInvestigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialCancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialA Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Shares Ovarian cancer and the tag pipeline.
- TrialA Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Shares Ovarian cancer and the tag pipeline.
- TrialEffect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome
Shares Ovarian cancer and the tag pipeline.